These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37863021)

  • 21. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021).
    Gonzalez Lopez de Turiso F; Guckian K
    Expert Opin Ther Pat; 2022 Apr; 32(4):365-379. PubMed ID: 35001782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
    Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
    J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
    Fang Z; Sun H; Wang Y; Sun Z; Yin M
    Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Yarmolinsky J; Amos CI; Hung RJ; Moreno V; Burrows K; Smith-Byrne K; Atkins JR; Brennan P; ; McKay JD; Martin RM; Davey Smith G
    Int J Cancer; 2022 Dec; 151(12):2155-2160. PubMed ID: 35747941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling.
    Virtanen A; Palmroth M; Liukkonen S; Kurttila A; Haikarainen T; Isomäki P; Silvennoinen O
    Arthritis Rheumatol; 2023 Nov; 75(11):2054-2061. PubMed ID: 37134144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
    Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
    J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of JAK/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: Systematic review and network meta-analysis.
    Zheng Y; Han Y; Chen J; Huang J; Zhu C; Lin L; Su H
    Indian J Dermatol Venereol Leprol; 2024; 90(5):590-598. PubMed ID: 38899421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
    Gooderham MJ; Hong HC; Litvinov IV
    Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The multiple-action allosteric inhibition of TYK2 by deucravacitinib: Insights from computational simulations.
    Bao Y; Xu R; Guo J
    Comput Biol Chem; 2024 Sep; 113():108224. PubMed ID: 39353258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
    Wang J; Batista VS; Bunick CG
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors.
    Jo CE; Gooderham M; Beecker J
    Int J Dermatol; 2022 Feb; 61(2):139-147. PubMed ID: 33929045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
    Wrobleski ST; Moslin R; Lin S; Zhang Y; Spergel S; Kempson J; Tokarski JS; Strnad J; Zupa-Fernandez A; Cheng L; Shuster D; Gillooly K; Yang X; Heimrich E; McIntyre KW; Chaudhry C; Khan J; Ruzanov M; Tredup J; Mulligan D; Xie D; Sun H; Huang C; D'Arienzo C; Aranibar N; Chiney M; Chimalakonda A; Pitts WJ; Lombardo L; Carter PH; Burke JR; Weinstein DS
    J Med Chem; 2019 Oct; 62(20):8973-8995. PubMed ID: 31318208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of a synthetic dual JAK1/TYK2 inhibitor in inflammatory bowel disease.
    Cui X; Teng Y; Hu Y; Li Q; Pei H; Yang Z
    Int Immunopharmacol; 2024 Jan; 126():111238. PubMed ID: 37988912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
    Martin G
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tyrosine kinase 2 inhibitors in autoimmune diseases.
    Ramakrishna C; Mason A; Edwards CJ
    Autoimmun Rev; 2024 Sep; 23(11):103649. PubMed ID: 39349269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planus.
    Stolte KN; Mesas-Fernández A; Meier K; Klein EK; Dommisch H; Ghoreschi K; Solimani F
    Exp Dermatol; 2024 Apr; 33(4):e15080. PubMed ID: 38628035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
    Huang MY; Armstrong AW
    Indian J Dermatol Venereol Leprol; 2023 [SEASON]; 90(1):30-40. PubMed ID: 38031699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition.
    Dragotto M; D'Onghia M; Trovato E; Tognetti L; Rubegni P; Calabrese L
    J Clin Med; 2024 May; 13(11):. PubMed ID: 38892802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
    Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
    Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent progress on tyrosine kinase 2 JH2 inhibitors.
    Deng L; Wan L; Liao T; Wang L; Wang J; Wu X; Shi J
    Int Immunopharmacol; 2023 Aug; 121():110434. PubMed ID: 37315371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.